

## **INFORMATION ONLY**

Introduction of HAEGARDA®

Customer Letter # 2021-18

2021-03-15

## Dear Colleagues:

Canadian Blood Services is pleased to announce that Haegarda®, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, is included on the Plasma Protein and Related Products formulary. Customers will be able to order Haegarda® **beginning the week of April 6th, 2021** using "Factor Concentrates & Other Plasma Protein Order Form".

A Patient Support Program will be made available. Please refer to the attached letter from CSL Behring for further details regarding the product.

## **Key Product Highlights:**

- Vial size: 2000 IU, 3000 IU
- Diluent: 4 mL (for 2000 IU) and 6 mL (for 3000 IU) Sterile Water of Injection
- Storage Temperature: +2°C to +30°C
- · Administration: Subcutaneous

Please see the attached Product Profile for additional information.

The following forms will be updated by April 1st, 2021 and posted on www.blood.ca:

- Factor Concentrates and Other Plasma Protein Products Order Form
- Plasma Protein Products Customer Table of Information

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.



This customer letter can also be viewed at <a href="www.blood.ca">www.blood.ca</a> in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier

Director, Plasma Protein and Related Products Formulary Program